It can be relatively easy to experience medical benefits from cannabis. A puff or two of tetrahydrocannabinol (THC)-rich flower can do the trick for a lot of people.
Although it may not be obvious during these Trump-rattled times, we’re in the midst of a psychedelic revival. There is more interest than ever before in experimenting with LSD, magic mushrooms, ayahuasca, ketamine, and other psychedelic drugs.
As you gaze upon these words, dear reader, a horde of alien marauders are ransacking all corners of the globe, chewing through the latest pharmaceutical defenses and leaving behind a gruesome trail of dead and weakened victims. According to a recent report by the World Health Organization (WHO), ferocious tribes of bacteria, parasites, viruses and fungi are on the rampage, and some are proving virtually invincible to the so-called “last resort” antibiotics.
The interactions between plant cannabinoids and a drug-metabolizing enzyme called carboxylesterase 1 (CES1) was recently published in Drug Metabolism and Distribution. Researchers at the Universities of Michigan and Florida showed that THC, CBD, and cannabinol (CBN) all inhibit CES1. CES1 is important for activating or inactivating drugs that regulate blood pressure, as well as the ADD drug Ritalin.
The endocannabinoid system is fundamental to addiction, but not in obvious ways. All sorts of cannabinoids appear to have anti-addictive properties: CBD, THCV, Rimonabant, THC. But Rimonabant acts by blocking the CB1 receptor, THC activates it, and CBD primarily functions in other ways.
These days it feels like CBD is everywhere. But if you’re looking for whole-plant, terpene-rich, high-CBD products – the kind that tends to be the most effective and that Project CBD recommends – these may be hard to find. That’s because high-resin cannabis plants with full-spectrum terpene expression typically also contain substantial amounts of tetrahydrocannabinol (THC).
Scientists in at Western New England University in Springfield, Massachusetts, briefly review 10 studies that shed light on how CBD might interact with cancer treatments.
Sometimes, science fails to see the tree for the forest. Statistical significance and double-blind trials are important, but so is human experience. Case studies are meaningful. Case studies often portend future discovery. So the case study of two Brazilian brain cancer patients who successfully combined CBD with their cancer treatment should not be dismissed. In their report, Paula Dall’Stella and other doctors in São Paulo describe the typical treatment plan for patients with glioblastoma.
Doctors in the UK recently reported the case of an elderly man who’s lung cancer responded to CBD. The man — being 81 years old — decided against chemotherapy or radiation, which would worsen his quality of life without much hope for extending it. Four months after a CT scan, the tumor cross section had shrunk to nearly one tenth of its initial size! The doctors — obviously surprised — found out that the patient had begun using a CBD oil 2-3 months earlier.